Advanced Search

 

Study ID Status Title Patient Level Data
ARIA1004 Completed An Evaluation of the Relative Bioavailability of the GI198745 (Dutasteride) Soft Gelatin Capsule with Monodiglycerides of Caprylic/Capric Acid (MDC) in Healthy Adult Male Volunteers
ARIA1007 Completed The Effects of Aging on the Pharmacokinetic and Pharmacodynamic Characteristics of GI198745/Dutasteride in Healthy Adult Male Volunteers
ARIA1009 Completed An Investigation of the Pharmacokinetics of GI198745 and of the Effects of GI198745 on Semen Characteristics When Administered Daily for 12 Months to Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
ARIA1010 Completed An Evaluation of the Effects of Cholestyramine on the Pharmacokinetics of GI198745(Dutasteride)
ARIA1011 Completed An Open-label, Crossover Study to Investigate the Pharmacokinetic-Pharmacodynamic Interaction Between (1) Tamsulosin and GI198745(dutasteride) and (2) Terazosin and GI198745 (dutasteride) When Co-administered to Healthy Male Subjects for 14 Days
ARIA1012 Completed Investiagtion of the Metabolic Fate and Routes of Excretion of GI198745 at Steady State in Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
ARIA2001 Completed A Double-Blind, Placebo-Controlled, Dose-Ranging, Clinical Evaluation of GI198745 and Finasteride in Subjects with Benign Prostatic Hyperplasia.
ARIA2003 Completed A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety And Preliminary Efficacy of Neoadjuvant Therapy With GI198745 in Subjects With Localized Prostate Cancer Undergoing Radical Prostatectomy. Study Listed on ClinicalStudyDataRequest.com
ARIA2004 Completed A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Evaluation of GI198745 and Finasteride in Subjects with Androgenetic Alopecia
ARIA3001_1 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Year 1 Data) Study Listed on ClinicalStudyDataRequest.com
ARIA3001_2 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data). Study Listed on ClinicalStudyDataRequest.com
ARIA3001_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIA3002 Completed A Randomized, double-blind, placebo-controlled, two year parallel group study of the efficacy and safety of GI198745 0.5 mg in the treatment and prevention of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIA3002_2 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data). Study Listed on ClinicalStudyDataRequest.com
ARIA3002_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIB2002 Completed A Randomised, Double-Blind, Placebo-Controlled, Double-Dummy Study of Dutasteride (GI198745) in Subjects Awaiting Transurethral Resection of the Prostate (TURP) for Treatment of Benign Prostatic Hyperplasia (BPH)
ARIB3003 Completed A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIB3003 Completed A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIB3003_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two Year Open-Label GI198745 Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIB3004 Completed A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension Study Listed on ClinicalStudyDataRequest.com
ARIB3004_1 Completed A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Repeat Dose Oral Dutasteride GI198745 on Detrusor Pressure and Urinary Flow in Patients with Lower Urinary Tract Symptoms Suggestive of Bladder Outlet Obstruction, with Optional Six Month Open-Label Extension. Study Listed on ClinicalStudyDataRequest.com
ARIF4012 Completed Multicentric, randomised, double-blind, double-dummy, parallel-group clinical trial evaluating short-term efficacy and safety of dutasteride compared to finasteride in patients presenting with BPH when switching from finasteride
ART108053 Completed An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications
Article-31 Completed Article 31 referral analyses of GSK’s clinical trial data to evaluate the risk of suicide, suicidal thoughts and behaviours, and self-harm, with particular attention to potential risk factors including age and gender
AUG102821 Completed A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.